ID   PNMT_HUMAN              Reviewed;         282 AA.
AC   P11086;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   07-APR-2021, entry version 190.
DE   RecName: Full=Phenylethanolamine N-methyltransferase;
DE            Short=PNMTase;
DE            EC=2.1.1.28;
DE   AltName: Full=Noradrenaline N-methyltransferase;
GN   Name=PNMT; Synonyms=PENT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3372503;
RA   Kaneda N., Ichinose H., Kobayashi K., Oka K., Kishi F., Nakazawa A.,
RA   Kurosawa Y., Fujita K., Nagatsu T.;
RT   "Molecular cloning of cDNA and chromosomal assignment of the gene for human
RT   phenylethanolamine N-methyltransferase, the enzyme for epinephrine
RT   biosynthesis.";
RL   J. Biol. Chem. 263:7672-7677(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RA   Sasaoka T., Kaneda N., Kurosawa Y., Fujita K., Nagatsu T.;
RT   "Structure of human phenylethanolamine N-methyltransferase gene: existence
RT   of two types of mRNA with different transcription initiation sites.";
RL   Neurochem. Int. 15:555-565(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2835776; DOI=10.1073/pnas.85.10.3648;
RA   Baetge E.E., Behringer R.R., Messing A., Brinster R.L., Palmiter R.D.;
RT   "Transgenic mice express the human phenylethanolamine N-methyltransferase
RT   gene in adrenal medulla and retina.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3648-3652(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-7, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH
RP   S-ADENOSYL-L-HOMOCYSTEINE AND SYNTHETIC INHIBITOR.
RX   PubMed=11591352; DOI=10.1016/s0969-2126(01)00662-1;
RA   Martin J.L., Begun J., McLeish M.J., Caine J.M., Grunewald G.L.;
RT   "Getting the adrenaline going: crystal structure of the adrenaline-
RT   synthesizing enzyme PNMT.";
RL   Structure 9:977-985(2001).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE ANALOGS
RP   AND S-ADENOSYL-L-HOMOCYSTEINE, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF TYR-35; GLU-185; GLU-219 AND ASP-267.
RX   PubMed=16363801; DOI=10.1021/bi051636b;
RA   Gee C.L., Tyndall J.D.A., Grunewald G.L., Wu Q., McLeish M.J., Martin J.L.;
RT   "Mode of binding of methyl acceptor substrates to the adrenaline-
RT   synthesizing enzyme phenylethanolamine N-methyltransferase: implications
RT   for catalysis.";
RL   Biochemistry 44:16875-16885(2005).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) IN COMPLEX WITH SYNTHETIC INHIBITOR.
RX   PubMed=16942016; DOI=10.1021/jm060466d;
RA   Grunewald G.L., Seim M.R., Regier R.C., Martin J.L., Gee C.L.,
RA   Drinkwater N., Criscione K.R.;
RT   "Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-
RT   tetrahydroisoquinolines with their isosteric sulfonamides to the active
RT   site of phenylethanolamine N-methyltransferase.";
RL   J. Med. Chem. 49:5424-5433(2006).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEXES WITH SYNTHETIC
RP   INHIBITOR.
RX   PubMed=17845018; DOI=10.1021/jm0703385;
RA   Gee C.L., Drinkwater N., Tyndall J.D.A., Grunewald G.L., Wu Q.,
RA   McLeish M.J., Martin J.L.;
RT   "Enzyme adaptation to inhibitor binding: a cryptic binding site in
RT   phenylethanolamine N-methyltransferase.";
RL   J. Med. Chem. 50:4845-4853(2007).
RN   [10]
RP   VARIANTS SER-9; ALA-98; CYS-112 AND THR-175, AND CHARACTERIZATION OF
RP   VARIANT ALA-98.
RX   PubMed=16277617; DOI=10.1111/j.1471-4159.2005.03453.x;
RA   Ji Y., Salavaggione O.E., Wang L., Adjei A.A., Eckloff B., Wieben E.D.,
RA   Weinshilboum R.M.;
RT   "Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-
RT   sequencing and functional genomics.";
RL   J. Neurochem. 95:1766-1776(2005).
CC   -!- FUNCTION: Converts noradrenaline to adrenaline.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=phenylethanolamine + S-adenosyl-L-methionine = H(+) + N-
CC         methylphenylethanolamine + S-adenosyl-L-homocysteine;
CC         Xref=Rhea:RHEA:12176, ChEBI:CHEBI:15378, ChEBI:CHEBI:57741,
CC         ChEBI:CHEBI:57856, ChEBI:CHEBI:57946, ChEBI:CHEBI:59789; EC=2.1.1.28;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=99 uM for phenylethanolamine {ECO:0000269|PubMed:16363801};
CC         KM=3.4 uM for S-adenosyl-L-methionine {ECO:0000269|PubMed:16363801};
CC   -!- PATHWAY: Catecholamine biosynthesis; (R)-adrenaline biosynthesis; (R)-
CC       adrenaline from (R)-noradrenaline: step 1/1.
CC   -!- INTERACTION:
CC       P11086; Q9P2G9-2: KLHL8; NbExp=3; IntAct=EBI-11305767, EBI-11959635;
CC       P11086; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-11305767, EBI-739832;
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding methyltransferase
CC       superfamily. NNMT/PNMT/TEMT family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J03727; AAA60130.1; -; mRNA.
DR   EMBL; X52730; CAA36944.1; -; Genomic_DNA.
DR   EMBL; J03280; AAA60131.1; -; Genomic_DNA.
DR   EMBL; BC037246; AAH37246.1; -; mRNA.
DR   CCDS; CCDS11343.1; -.
DR   PIR; A28171; A28171.
DR   RefSeq; NP_002677.1; NM_002686.4.
DR   PDB; 1HNN; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 1N7I; X-ray; 2.80 A; A/B=1-282.
DR   PDB; 1N7J; X-ray; 2.70 A; A/B=1-282.
DR   PDB; 1YZ3; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 2AN3; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 2AN4; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 2AN5; X-ray; 2.50 A; A/B=1-282.
DR   PDB; 2G70; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 2G71; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 2G72; X-ray; 2.00 A; A/B=1-282.
DR   PDB; 2G8N; X-ray; 2.15 A; A/B=1-282.
DR   PDB; 2OBF; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 2ONY; X-ray; 2.60 A; A/B=1-282.
DR   PDB; 2ONZ; X-ray; 2.80 A; A/B=1-282.
DR   PDB; 2OPB; X-ray; 2.80 A; A/B=1-282.
DR   PDB; 3HCA; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3HCB; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3HCC; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 3HCD; X-ray; 2.39 A; A/B=1-282.
DR   PDB; 3HCE; X-ray; 2.85 A; A/B=1-282.
DR   PDB; 3HCF; X-ray; 2.70 A; A/B=1-282.
DR   PDB; 3KPJ; X-ray; 2.50 A; A/B=1-282.
DR   PDB; 3KPU; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KPV; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KPW; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KPY; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQM; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQO; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQP; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQQ; X-ray; 2.50 A; A/B=1-282.
DR   PDB; 3KQS; X-ray; 2.00 A; A/B=1-282.
DR   PDB; 3KQT; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 3KQV; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 3KQW; X-ray; 2.49 A; A/B=1-282.
DR   PDB; 3KQY; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 3KR0; X-ray; 2.60 A; A/B=1-282.
DR   PDB; 3KR1; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 3KR2; X-ray; 2.30 A; A/B=1-282.
DR   PDB; 4DM3; X-ray; 2.40 A; A/B=1-282.
DR   PDB; 4MIK; X-ray; 1.95 A; A/B=1-282.
DR   PDB; 4MQ4; X-ray; 2.20 A; A/B=1-282.
DR   PDB; 6WS1; X-ray; 2.76 A; A/B=1-282.
DR   PDBsum; 1HNN; -.
DR   PDBsum; 1N7I; -.
DR   PDBsum; 1N7J; -.
DR   PDBsum; 1YZ3; -.
DR   PDBsum; 2AN3; -.
DR   PDBsum; 2AN4; -.
DR   PDBsum; 2AN5; -.
DR   PDBsum; 2G70; -.
DR   PDBsum; 2G71; -.
DR   PDBsum; 2G72; -.
DR   PDBsum; 2G8N; -.
DR   PDBsum; 2OBF; -.
DR   PDBsum; 2ONY; -.
DR   PDBsum; 2ONZ; -.
DR   PDBsum; 2OPB; -.
DR   PDBsum; 3HCA; -.
DR   PDBsum; 3HCB; -.
DR   PDBsum; 3HCC; -.
DR   PDBsum; 3HCD; -.
DR   PDBsum; 3HCE; -.
DR   PDBsum; 3HCF; -.
DR   PDBsum; 3KPJ; -.
DR   PDBsum; 3KPU; -.
DR   PDBsum; 3KPV; -.
DR   PDBsum; 3KPW; -.
DR   PDBsum; 3KPY; -.
DR   PDBsum; 3KQM; -.
DR   PDBsum; 3KQO; -.
DR   PDBsum; 3KQP; -.
DR   PDBsum; 3KQQ; -.
DR   PDBsum; 3KQS; -.
DR   PDBsum; 3KQT; -.
DR   PDBsum; 3KQV; -.
DR   PDBsum; 3KQW; -.
DR   PDBsum; 3KQY; -.
DR   PDBsum; 3KR0; -.
DR   PDBsum; 3KR1; -.
DR   PDBsum; 3KR2; -.
DR   PDBsum; 4DM3; -.
DR   PDBsum; 4MIK; -.
DR   PDBsum; 4MQ4; -.
DR   PDBsum; 6WS1; -.
DR   PCDDB; P11086; -.
DR   SMR; P11086; -.
DR   BioGRID; 111410; 12.
DR   IntAct; P11086; 5.
DR   STRING; 9606.ENSP00000269582; -.
DR   BindingDB; P11086; -.
DR   ChEMBL; CHEMBL4617; -.
DR   DrugBank; DB08129; (1R)-2-amino-1-[3-(trifluoromethyl)phenyl]ethanol.
DR   DrugBank; DB08128; (1S,4R,9S)-5-(trifluoromethyl)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-9-amine.
DR   DrugBank; DB07739; (3R)-3-(FLUOROMETHYL)-7-(THIOMORPHOLIN-4-YLSULFONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE.
DR   DrugBank; DB07798; (3R)-3-(FLUOROMETHYL)-N-(3,3,3-TRIFLUOROPROPYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE.
DR   DrugBank; DB07747; (3R)-N-(4-CHLOROPHENYL)-3-(HYDROXYMETHYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE.
DR   DrugBank; DB03468; 1,2,3,4-Tetrahydro-Isoquinoline-7-Sulfonic Acid Amide.
DR   DrugBank; DB08550; 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
DR   DrugBank; DB03824; 7-Iodo-1,2,3,4-Tetrahydro-Isoquinoline.
DR   DrugBank; DB04273; 8,9-Dichloro-2,3,4,5-Tetrahydro-1h-Benzo[C]Azepine.
DR   DrugBank; DB07906; [(3R)-7-NITRO-1,2,3,4-TETRAHYDROISOQUINOLIN-3-YL]METHANOL.
DR   DrugBank; DB07597; CIS-(1R,2S)-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL.
DR   DrugBank; DB09571; Levmetamfetamine.
DR   DrugBank; DB08631; N-(4-CHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE.
DR   DrugBank; DB01752; S-adenosyl-L-homocysteine.
DR   DrugBank; DB08654; TRANS-(1S,2S)-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL.
DR   DrugCentral; P11086; -.
DR   GuidetoPHARMACOLOGY; 2496; -.
DR   iPTMnet; P11086; -.
DR   PhosphoSitePlus; P11086; -.
DR   BioMuta; PNMT; -.
DR   DMDM; 130375; -.
DR   CPTAC; CPTAC-150; -.
DR   CPTAC; CPTAC-151; -.
DR   MassIVE; P11086; -.
DR   PaxDb; P11086; -.
DR   PeptideAtlas; P11086; -.
DR   PRIDE; P11086; -.
DR   ProteomicsDB; 52692; -.
DR   Antibodypedia; 28325; 488 antibodies.
DR   CPTC; P11086; 3 antibodies.
DR   DNASU; 5409; -.
DR   Ensembl; ENST00000269582; ENSP00000269582; ENSG00000141744.
DR   GeneID; 5409; -.
DR   KEGG; hsa:5409; -.
DR   UCSC; uc002hsi.3; human.
DR   CTD; 5409; -.
DR   DisGeNET; 5409; -.
DR   GeneCards; PNMT; -.
DR   HGNC; HGNC:9160; PNMT.
DR   HPA; ENSG00000141744; Group enriched (adrenal gland, ductus deferens, seminal vesicle).
DR   MIM; 171190; gene.
DR   neXtProt; NX_P11086; -.
DR   OpenTargets; ENSG00000141744; -.
DR   Orphanet; 243761; NON RARE IN EUROPE: Essential hypertension.
DR   PharmGKB; PA274; -.
DR   VEuPathDB; HostDB:ENSG00000141744.3; -.
DR   eggNOG; ENOG502QT44; Eukaryota.
DR   GeneTree; ENSGT00390000011708; -.
DR   HOGENOM; CLU_082526_2_0_1; -.
DR   InParanoid; P11086; -.
DR   OMA; AFDWSVY; -.
DR   OrthoDB; 1054662at2759; -.
DR   PhylomeDB; P11086; -.
DR   TreeFam; TF313114; -.
DR   BioCyc; MetaCyc:HS06868-MONOMER; -.
DR   BRENDA; 2.1.1.28; 2681.
DR   PathwayCommons; P11086; -.
DR   Reactome; R-HSA-209905; Catecholamine biosynthesis.
DR   UniPathway; UPA00749; UER00736.
DR   BioGRID-ORCS; 5409; 9 hits in 992 CRISPR screens.
DR   EvolutionaryTrace; P11086; -.
DR   GenomeRNAi; 5409; -.
DR   Pharos; P11086; Tchem.
DR   PRO; PR:P11086; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P11086; protein.
DR   Bgee; ENSG00000141744; Expressed in adrenal gland and 170 other tissues.
DR   ExpressionAtlas; P11086; baseline and differential.
DR   Genevisible; P11086; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0008170; F:N-methyltransferase activity; IBA:GO_Central.
DR   GO; GO:0004603; F:phenylethanolamine N-methyltransferase activity; IBA:GO_Central.
DR   GO; GO:0042423; P:catecholamine biosynthetic process; TAS:Reactome.
DR   GO; GO:0042418; P:epinephrine biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0032259; P:methylation; IEA:UniProtKB-KW.
DR   InterPro; IPR025820; NNMT/PNMT/TEMT_CS.
DR   InterPro; IPR000940; NNMT_TEMT_trans.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   PANTHER; PTHR10867; PTHR10867; 1.
DR   Pfam; PF01234; NNMT_PNMT_TEMT; 1.
DR   PIRSF; PIRSF000384; PNMTase; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS01100; NNMT_PNMT_TEMT; 1.
DR   PROSITE; PS51681; SAM_MT_NNMT_PNMT_TEMT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Catecholamine biosynthesis; Methyltransferase;
KW   Phosphoprotein; Reference proteome; S-adenosyl-L-methionine; Transferase.
FT   CHAIN           1..282
FT                   /note="Phenylethanolamine N-methyltransferase"
FT                   /id="PRO_0000159709"
FT   REGION          79..80
FT                   /note="S-adenosyl-L-methionine binding"
FT   REGION          158..159
FT                   /note="S-adenosyl-L-methionine binding"
FT   BINDING         35
FT                   /note="S-adenosyl-L-methionine"
FT   BINDING         40
FT                   /note="S-adenosyl-L-methionine"
FT   BINDING         85
FT                   /note="S-adenosyl-L-methionine"
FT   BINDING         101
FT                   /note="S-adenosyl-L-methionine"
FT   BINDING         106
FT                   /note="S-adenosyl-L-methionine"
FT   BINDING         181
FT                   /note="S-adenosyl-L-methionine; via carbonyl oxygen"
FT   BINDING         219
FT                   /note="Substrate"
FT   MOD_RES         7
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         9
FT                   /note="N -> S (in dbSNP:rs11569781)"
FT                   /evidence="ECO:0000269|PubMed:16277617"
FT                   /id="VAR_029351"
FT   VARIANT         98
FT                   /note="T -> A (lower activity levels than wild-type;
FT                   dbSNP:rs36060376)"
FT                   /evidence="ECO:0000269|PubMed:16277617"
FT                   /id="VAR_036829"
FT   VARIANT         112
FT                   /note="R -> C (in dbSNP:rs34530498)"
FT                   /evidence="ECO:0000269|PubMed:16277617"
FT                   /id="VAR_036830"
FT   VARIANT         175
FT                   /note="A -> T (in dbSNP:rs34341496)"
FT                   /evidence="ECO:0000269|PubMed:16277617"
FT                   /id="VAR_036831"
FT   VARIANT         188
FT                   /note="S -> C (in dbSNP:rs5639)"
FT                   /id="VAR_037611"
FT   VARIANT         211
FT                   /note="L -> H (in dbSNP:rs5640)"
FT                   /id="VAR_037612"
FT   VARIANT         217
FT                   /note="L -> Q (in dbSNP:rs5641)"
FT                   /id="VAR_037613"
FT   VARIANT         254
FT                   /note="R -> H (in dbSNP:rs5642)"
FT                   /id="VAR_037614"
FT   VARIANT         276
FT                   /note="W -> R (in dbSNP:rs5643)"
FT                   /id="VAR_024547"
FT   MUTAGEN         35
FT                   /note="Y->F: Strongly increases KM for substrate and S-
FT                   adenosyl-L-methionine."
FT                   /evidence="ECO:0000269|PubMed:16363801"
FT   MUTAGEN         185
FT                   /note="E->A,Q: Strongly reduced enzyme activity. Increases
FT                   affinity for S-adenosyl-L-methionine."
FT                   /evidence="ECO:0000269|PubMed:16363801"
FT   MUTAGEN         185
FT                   /note="E->D: Strongly reduced enzyme activity. Decreases
FT                   affinity for substrate and S-adenosyl-L-methionine 3-fold."
FT                   /evidence="ECO:0000269|PubMed:16363801"
FT   MUTAGEN         219
FT                   /note="E->A: Reduced enzyme activity. Decreases affinity
FT                   for substrate 6-fold. Decreases affinity for S-adenosyl-L-
FT                   methionine 2-fold."
FT                   /evidence="ECO:0000269|PubMed:16363801"
FT   MUTAGEN         267
FT                   /note="D->A,N: Strongly reduced enzyme activity. Decreases
FT                   affinity for substrate 200-fold. Decreases affinity for S-
FT                   adenosyl-L-methionine 3-fold."
FT                   /evidence="ECO:0000269|PubMed:16363801"
FT   CONFLICT        169..170
FT                   /note="SP -> AQ (in Ref. 3; AAA60131)"
FT                   /evidence="ECO:0000305"
FT   HELIX           17..25
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           27..29
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           32..40
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   TURN            42..45
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           53..66
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          73..79
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           85..87
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           90..92
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          95..100
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           104..114
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           124..134
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           140..150
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          151..155
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          161..163
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          173..182
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   TURN            184..186
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           191..202
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          205..218
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          221..224
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          227..230
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           236..246
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          248..257
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   HELIX           260..262
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          265..267
FT                   /evidence="ECO:0007744|PDB:4MIK"
FT   STRAND          271..279
FT                   /evidence="ECO:0007744|PDB:4MIK"
SQ   SEQUENCE   282 AA;  30855 MW;  56F3A9981D9ABF4C CRC64;
     MSGADRSPNA GAAPDSAPGQ AAVASAYQRF EPRAYLRNNY APPRGDLCNP NGVGPWKLRC
     LAQTFATGEV SGRTLIDIGS GPTVYQLLSA CSHFEDITMT DFLEVNRQEL GRWLQEEPGA
     FNWSMYSQHA CLIEGKGECW QDKERQLRAR VKRVLPIDVH QPQPLGAGSP APLPADALVS
     AFCLEAVSPD LASFQRALDH ITTLLRPGGH LLLIGALEES WYLAGEARLT VVPVSEEEVR
     EALVRSGYKV RDLRTYIMPA HLQTGVDDVK GVFFAWAQKV GL
//
